{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:09:39Z","timestamp":1793891379259,"version":"4.8.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Disulfiram and metals inactivate key oncoproteins resulting in anti-neoplastic activity. The goal of this study was to determine the maximum tolerated dose of copper when administered with disulfiram in patients with advanced solid tumors and liver involvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Disulfiram 250\u2009mg was administered daily in 28-day\u2009cycles. Four doses of copper gluconate were tested (2, 4, 6, and 8\u2009mg\u00a0of elemental copper) in a standard 3\u2009+\u20093 dose escalation design. Patients were evaluated for dose limiting toxicities and response. Protein<jats:italic>S<\/jats:italic>-glutathionylation was evaluated as a pharmacodynamic marker.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-one patients were enrolled and 16 patients were evaluable for dose limiting toxicities. Among the 21 patients, there was a median of 4 lines of prior chemotherapy. Five Grade 3 toxicities were observed (anorexia, elevated aspartate aminotransferase or AST, elevated alkaline phosphatase, fever, and fatigue). Response data was available for 15 patients. Four patients had stable disease with the longest duration of disease control being 116\u2009days. The median duration of treatment for evaluable patients was 55\u2009days (range 28\u2013124). Reasons for discontinuation included functional decline, disease progression, and disease-associated death. Increased<jats:italic>S<\/jats:italic>-glutathionylation of serum proteins was observed with treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Disulfiram 250\u2009mg daily with copper gluconate (8 mg of elemental copper)\u00a0was well-tolerated in patients with solid tumors involving the liver and was not associated with dose limiting toxicities. While temporary disease stabilization was noted in some patients, no objective responses were observed. Treatment was associated with an increase in<jats:italic>S<\/jats:italic>-glutathionylation suggesting that this combination could exert a suppressive effect on cellular growth and protein function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00742911\">NCT00742911<\/jats:ext-link>, first posted 28\/08\/2008.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-021-08242-4","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T02:02:52Z","timestamp":1620352972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker"],"prefix":"10.1186","volume":"21","author":[{"given":"Kristen C.","family":"Kelley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth F.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Brittain-Blankenship","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli M.","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace L.","family":"Akerley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moises C.","family":"Terrazas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken M.","family":"Kosak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saundra S.","family":"Buys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa L.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Shami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"8242_CR1","first-page":"63","volume":"58","author":"HK Schirmer","year":"1966","unstructured":"Schirmer HK, Scott WW. Disulfiram and tumor inhibition. Trans Am Assoc Genitourin Surg. 1966;58:63\u20136.","journal-title":"Trans Am Assoc Genitourin Surg"},{"issue":"16","key":"8242_CR2","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1021\/ja109413c","volume":"133","author":"S Tardito","year":"2011","unstructured":"Tardito S, Bassanetti I, Bignardi C, Elviri L, Tegoni M, Mucchino C, et al. Copper binding agents acting as copper ionophores lead to caspase inhibition and paraptotic cell death in human cancer cells. J Am Chem Soc. 2011;133(16):6235\u201342. https:\/\/doi.org\/10.1021\/ja109413c.","journal-title":"J Am Chem Soc"},{"issue":"4","key":"8242_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.2174\/0929867324666171023161121","volume":"25","author":"M Viola-Rhenals","year":"2018","unstructured":"Viola-Rhenals M, Patel KR, Jaimes-Santamaria L, Wu G, Liu J, Dou QP. Recent advances in Antabuse (Disulfiram): the importance of its metal-binding ability to its anticancer activity. Curr Med Chem. 2018;25(4):506\u201324. https:\/\/doi.org\/10.2174\/0929867324666171023161121.","journal-title":"Curr Med Chem"},{"issue":"1","key":"8242_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/CMR.0b013e328334131d","volume":"20","author":"BW Morrison","year":"2010","unstructured":"Morrison BW, Doudican NA, Patel KR, Orlow SJ. Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma. Melanoma Res. 2010;20(1):11\u201320. https:\/\/doi.org\/10.1097\/CMR.0b013e328334131d.","journal-title":"Melanoma Res"},{"issue":"10","key":"8242_CR5","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.4161\/cc.28959","volume":"13","author":"A Bruning","year":"2014","unstructured":"Bruning A, Kast RE. Oxidizing to death: disulfiram for cancer cell killing. Cell Cycle. 2014;13(10):1513\u20134. https:\/\/doi.org\/10.4161\/cc.28959.","journal-title":"Cell Cycle"},{"issue":"6","key":"8242_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0891-5849(94)90091-4","volume":"17","author":"S Mankhetkorn","year":"1994","unstructured":"Mankhetkorn S, Abedinzadeh Z, Houee-Levin C. Antioxidant action of sodium diethyldithiocarbamate: reaction with hydrogen peroxide and superoxide radical. Free Radic Biol Med. 1994;17(6):517\u201327. https:\/\/doi.org\/10.1016\/0891-5849(94)90091-4.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"8242_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0891-5849(89)90006-3","volume":"7","author":"AL Zanocco","year":"1989","unstructured":"Zanocco AL, Pavez R, Videla LA, Lissi EA. Antioxidant capacity of diethyldithiocarbamate in a metal independent lipid peroxidative process. Free Radic Biol Med. 1989;7(2):151\u20136. https:\/\/doi.org\/10.1016\/0891-5849(89)90006-3.","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"8242_CR8","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/bjc.2011.126","volume":"104","author":"NC Yip","year":"2011","unstructured":"Yip NC, Fombon IS, Liu P, Brown S, Kannappan V, Armesilla AL, et al. Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer. 2011;104(10):1564\u201374. https:\/\/doi.org\/10.1038\/bjc.2011.126.","journal-title":"Br J Cancer"},{"issue":"5","key":"8242_CR9","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1084\/jem.175.5.1181","volume":"175","author":"R Schreck","year":"1992","unstructured":"Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med. 1992;175(5):1181\u201394. https:\/\/doi.org\/10.1084\/jem.175.5.1181.","journal-title":"J Exp Med"},{"issue":"1","key":"8242_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2015.07.029","volume":"369","author":"Y Li","year":"2015","unstructured":"Li Y, Fu SY, Wang LH, Wang FY, Wang NN, Cao Q, et al. Copper improves the anti-angiogenic activity of disulfiram through the EGFR\/Src\/VEGF pathway in gliomas. Cancer Lett. 2015;369(1):86\u201396. https:\/\/doi.org\/10.1016\/j.canlet.2015.07.029.","journal-title":"Cancer Lett"},{"issue":"9","key":"8242_CR11","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/1535-7163.1049.3.9","volume":"3","author":"SS Brar","year":"2004","unstructured":"Brar SS, Grigg C, Wilson KS, Holder WD Jr, Dreau D, Austin C, et al. Disulfiram inhibits activating transcription factor\/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther. 2004;3(9):1049\u201360.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"8242_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/(SICI)1098-2744(199808)22:4<235::AID-MC5>3.0.CO;2-I","volume":"22","author":"GY Liu","year":"1998","unstructured":"Liu GY, Frank N, Bartsch H, Lin JK. Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFkappaB, c-fos\/c-Jun, and p53 proteins. Mol Carcinog. 1998;22(4):235\u201346. https:\/\/doi.org\/10.1002\/(SICI)1098-2744(199808)22:4<235::AID-MC5>3.0.CO;2-I.","journal-title":"Mol Carcinog"},{"issue":"4","key":"8242_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/pros.21247","volume":"71","author":"J Lin","year":"2011","unstructured":"Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate. 2011;71(4):333\u201343. https:\/\/doi.org\/10.1002\/pros.21247.","journal-title":"Prostate."},{"issue":"1","key":"8242_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cbi.2007.09.004","volume":"171","author":"J Chen","year":"2008","unstructured":"Chen J, Du C, Kang J, Wang J. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis. Chem Biol Interact. 2008;171(1):26\u201336. https:\/\/doi.org\/10.1016\/j.cbi.2007.09.004.","journal-title":"Chem Biol Interact"},{"issue":"6","key":"8242_CR15","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/ijc.21534","volume":"118","author":"H Lovborg","year":"2006","unstructured":"Lovborg H, Oberg F, Rickardson L, Gullbo J, Nygren P, Larsson R. Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Int J Cancer. 2006;118(6):1577\u201380. https:\/\/doi.org\/10.1002\/ijc.21534.","journal-title":"Int J Cancer"},{"issue":"21","key":"8242_CR16","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.1158\/0008-5472.CAN-06-2126","volume":"66","author":"D Chen","year":"2006","unstructured":"Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006;66(21):10425\u201333. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2126.","journal-title":"Cancer Res"},{"issue":"21","key":"8242_CR17","doi-asserted-by":"publisher","first-page":"10478","DOI":"10.1158\/0008-5472.CAN-06-3017","volume":"66","author":"V Milacic","year":"2006","unstructured":"Milacic V, Chen D, Ronconi L, Landis-Piwowar KR, Fregona D, Dou QP. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res. 2006;66(21):10478\u201386. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3017.","journal-title":"Cancer Res"},{"issue":"20","key":"8242_CR18","doi-asserted-by":"publisher","first-page":"6256","DOI":"10.1021\/jm8007807","volume":"51","author":"B Cvek","year":"2008","unstructured":"Cvek B, Milacic V, Taraba J, Dou QP. Ni(II), cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. J Med Chem. 2008;51(20):6256\u20138. https:\/\/doi.org\/10.1021\/jm8007807.","journal-title":"J Med Chem"},{"issue":"1-3","key":"8242_CR19","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.2741\/1749","volume":"10","author":"D Chen","year":"2005","unstructured":"Chen D, Peng F, Cui QC, Daniel KG, Orlu S, Liu J, et al. Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosci. 2005;10(1-3):2932\u20139. https:\/\/doi.org\/10.2741\/1749.","journal-title":"Front Biosci"},{"issue":"6","key":"8242_CR20","doi-asserted-by":"publisher","first-page":"R897","DOI":"10.1186\/bcr1322","volume":"7","author":"KG Daniel","year":"2005","unstructured":"Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res. 2005;7(6):R897\u2013908. https:\/\/doi.org\/10.1186\/bcr1322.","journal-title":"Breast Cancer Res"},{"issue":"6","key":"8242_CR21","first-page":"919","volume":"20","author":"Z Yu","year":"2007","unstructured":"Yu Z, Wang F, Milacic V, Li X, Cui QC, Zhang B, et al. Evaluation of copper-dependent proteasome-inhibitory and apoptosis-inducing activities of novel pyrrolidine dithiocarbamate analogues. Int J Mol Med. 2007;20(6):919\u201325.","journal-title":"Int J Mol Med"},{"issue":"1","key":"8242_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.taap.2008.03.009","volume":"231","author":"V Milacic","year":"2008","unstructured":"Milacic V, Chen D, Giovagnini L, Diez A, Fregona D, Dou QP. Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity. Toxicol Appl Pharmacol. 2008;231(1):24\u201333. https:\/\/doi.org\/10.1016\/j.taap.2008.03.009.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"8242_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/ijc.1565","volume":"97","author":"M Marikovsky","year":"2002","unstructured":"Marikovsky M, Nevo N, Vadai E, Harris-Cerruti C. Cu\/Zn superoxide dismutase plays a role in angiogenesis. Int J Cancer. 2002;97(1):34\u201341. https:\/\/doi.org\/10.1002\/ijc.1565.","journal-title":"Int J Cancer"},{"issue":"5","key":"8242_CR24","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1124\/mol.64.5.1076","volume":"64","author":"SG Shian","year":"2003","unstructured":"Shian SG, Kao YR, Wu FY, Wu CW. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol Pharmacol. 2003;64(5):1076\u201384. https:\/\/doi.org\/10.1124\/mol.64.5.1076.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"8242_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0009-2797(01)00283-6","volume":"138","author":"MY Balakirev","year":"2001","unstructured":"Balakirev MY, Zimmer G. Mitochondrial injury by disulfiram: two different mechanisms of the mitochondrial permeability transition. Chem Biol Interact. 2001;138(3):299\u2013311. https:\/\/doi.org\/10.1016\/S0009-2797(01)00283-6.","journal-title":"Chem Biol Interact"},{"issue":"3","key":"8242_CR26","first-page":"197","volume":"1","author":"D Cen","year":"2002","unstructured":"Cen D, Gonzalez RI, Buckmeier JA, Kahlon RS, Tohidian NB, Meyskens FL Jr. Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther. 2002;1(3):197\u2013204.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"8242_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1081\/CNV-67147","volume":"23","author":"L Malaguarnera","year":"2005","unstructured":"Malaguarnera L, Pilastro MR, Vicari L, Dimarco R, Manzella L, Palumbo G, et al. Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity. Cancer Investig. 2005;23(5):404\u201312. https:\/\/doi.org\/10.1081\/CNV-67147.","journal-title":"Cancer Investig"},{"issue":"12","key":"8242_CR28","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1093\/ndt\/gfl543","volume":"21","author":"C Morais","year":"2006","unstructured":"Morais C, Pat B, Gobe G, Johnson DW, Healy H. Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines. Nephrol Dial Transplant. 2006;21(12):3377\u201388. https:\/\/doi.org\/10.1093\/ndt\/gfl543.","journal-title":"Nephrol Dial Transplant"},{"issue":"27","key":"8242_CR29","doi-asserted-by":"publisher","first-page":"6914","DOI":"10.1021\/jm049568z","volume":"47","author":"D Cen","year":"2004","unstructured":"Cen D, Brayton D, Shahandeh B, Meyskens FL Jr, Farmer PJ. Disulfiram facilitates intracellular cu uptake and induces apoptosis in human melanoma cells. J Med Chem. 2004;47(27):6914\u201320. https:\/\/doi.org\/10.1021\/jm049568z.","journal-title":"J Med Chem"},{"issue":"10","key":"8242_CR30","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.chembiol.2007.08.016","volume":"14","author":"D Saggioro","year":"2007","unstructured":"Saggioro D, Rigobello MP, Paloschi L, Folda A, Moggach SA, Parsons S, et al. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem Biol. 2007;14(10):1128\u201339. https:\/\/doi.org\/10.1016\/j.chembiol.2007.08.016.","journal-title":"Chem Biol"},{"issue":"1\u20133","key":"8242_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejphar.2008.07.024","volume":"594","author":"SH Chen","year":"2008","unstructured":"Chen SH, Lin JK, Liang YC, Pan MH, Liu SH, Lin-Shiau SY. Involvement of activating transcription factors JNK, NF-kappaB, and AP-1 in apoptosis induced by pyrrolidine dithiocarbamate\/cu complex. Eur J Pharmacol. 2008;594(1\u20133):9\u201317. https:\/\/doi.org\/10.1016\/j.ejphar.2008.07.024.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"8242_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1039\/b504392a","volume":"1","author":"ZE Sauna","year":"2005","unstructured":"Sauna ZE, Shukla S, Ambudkar SV. Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Mol BioSyst. 2005;1(2):127\u201334. https:\/\/doi.org\/10.1039\/b504392a.","journal-title":"Mol BioSyst"},{"issue":"11","key":"8242_CR33","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/jnci\/92.11.898","volume":"92","author":"TW Loo","year":"2000","unstructured":"Loo TW, Clarke DM. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst. 2000;92(11):898\u2013902. https:\/\/doi.org\/10.1093\/jnci\/92.11.898.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"8242_CR34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1021\/mp049917l","volume":"1","author":"TW Loo","year":"2004","unstructured":"Loo TW, Bartlett MC, Clarke DM. Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol Pharm. 2004;1(6):426\u201333. https:\/\/doi.org\/10.1021\/mp049917l.","journal-title":"Mol Pharm"},{"issue":"3","key":"8242_CR35","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1124\/pr.111.005538","volume":"64","author":"V Koppaka","year":"2012","unstructured":"Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO, et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol Rev. 2012;64(3):520\u201339. https:\/\/doi.org\/10.1124\/pr.111.005538.","journal-title":"Pharmacol Rev"},{"issue":"4","key":"8242_CR36","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/ijc.10972","volume":"104","author":"W Wang","year":"2003","unstructured":"Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer. 2003;104(4):504\u201311. https:\/\/doi.org\/10.1002\/ijc.10972.","journal-title":"Int J Cancer"},{"issue":"4","key":"8242_CR37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s10495-009-0414-y","volume":"15","author":"C Morais","year":"2010","unstructured":"Morais C, Gobe G, Johnson DW, Healy H. Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma. Apoptosis. 2010;15(4):412\u201325. https:\/\/doi.org\/10.1007\/s10495-009-0414-y.","journal-title":"Apoptosis."},{"issue":"8","key":"8242_CR38","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.freeradbiomed.2011.01.001","volume":"50","author":"E Dalla Pozza","year":"2011","unstructured":"Dalla Pozza E, Donadelli M, Costanzo C, Zaniboni T, Dando I, Franchini M, et al. Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives. Free Radic Biol Med. 2011;50(8):926\u201333. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2011.01.001.","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"8242_CR39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bcmd.2011.08.004","volume":"47","author":"B Xu","year":"2011","unstructured":"Xu B, Shi P, Fombon IS, Zhang Y, Huang F, Wang W, et al. Disulfiram\/copper complex activated JNK\/c-Jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells. Blood Cells Mol Dis. 2011;47(4):264\u20139. https:\/\/doi.org\/10.1016\/j.bcmd.2011.08.004.","journal-title":"Blood Cells Mol Dis"},{"issue":"10","key":"8242_CR40","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.18632\/oncotarget.604","volume":"3","author":"J Triscott","year":"2012","unstructured":"Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, et al. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget. 2012;3(10):1112\u201323. https:\/\/doi.org\/10.18632\/oncotarget.604.","journal-title":"Oncotarget."},{"issue":"4","key":"8242_CR41","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3892\/ijo.2014.2564","volume":"45","author":"S Tahata","year":"2014","unstructured":"Tahata S, Yuan B, Kikuchi H, Takagi N, Hirano T, Toyoda H. Cytotoxic effects of pyrrolidine dithiocarbamate in small-cell lung cancer cells, alone and in combination with cisplatin. Int J Oncol. 2014;45(4):1749\u201359. https:\/\/doi.org\/10.3892\/ijo.2014.2564.","journal-title":"Int J Oncol"},{"issue":"3","key":"8242_CR42","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11060-019-03125-y","volume":"142","author":"J Huang","year":"2019","unstructured":"Huang J, Chaudhary R, Cohen AL, Fink K, Goldlust S, Boockvar J, et al. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. J Neuro-Oncol. 2019;142(3):537\u201344. https:\/\/doi.org\/10.1007\/s11060-019-03125-y.","journal-title":"J Neuro-Oncol"},{"issue":"4","key":"8242_CR43","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/pcan.2013.28","volume":"16","author":"MT Schweizer","year":"2013","unstructured":"Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, et al. Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2013;16(4):357\u201361. https:\/\/doi.org\/10.1038\/pcan.2013.28.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8 Supplement","key":"8242_CR44","first-page":"LB","volume":"73","author":"KF Grossmann","year":"2013","unstructured":"Grossmann KF, Terrazas M, Khong HT, Akerley W, Kosak K, Boucher K, et al. Abstract LB-175: Phase II study of disulfiram and chelated Zn for the treatment of disseminated metastatic melanoma. Cancer Res. 2013;73(8 Supplement):LB\u2013175.","journal-title":"Cancer Res"},{"issue":"2","key":"8242_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00000421-199004000-00007","volume":"13","author":"S Verma","year":"1990","unstructured":"Verma S, Stewart DJ, Maroun JA, Nair RC. A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram. Am J Clin Oncol. 1990;13(2):119\u201324. https:\/\/doi.org\/10.1097\/00000421-199004000-00007.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"8242_CR46","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1634\/theoncologist.2014-0424","volume":"20","author":"H Nechushtan","year":"2015","unstructured":"Nechushtan H, Hamamreh Y, Nidal S, Gotfried M, Baron A, Shalev YI, et al. A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. Oncologist. 2015;20(4):366\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2014-0424.","journal-title":"Oncologist."},{"issue":"34","key":"8242_CR47","doi-asserted-by":"publisher","first-page":"55368","DOI":"10.18632\/oncotarget.10552","volume":"7","author":"J de Ridder","year":"2016","unstructured":"de Ridder J, de Wilt JH, Simmer F, Overbeek L, Lemmens V, Nagtegaal I. Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients. Oncotarget. 2016;7(34):55368\u201376. https:\/\/doi.org\/10.18632\/oncotarget.10552.","journal-title":"Oncotarget."},{"key":"8242_CR48","doi-asserted-by":"crossref","unstructured":"Denoyer D, E S, Cater MA. Targeting copper in cancer therapy: \u2018Copper that Cancer\u2019. Metallomics. 2015;7(11):1459-76. Masaldan S, La Fontain.","DOI":"10.1039\/C5MT00149H"},{"issue":"50","key":"8242_CR49","doi-asserted-by":"publisher","first-page":"82200","DOI":"10.18632\/oncotarget.9413","volume":"7","author":"M Deng","year":"2016","unstructured":"Deng M, Jiang Z, Li Y, Zhou Y, Li J, Wang X, et al. Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram\/copper complex in vitro and in vivo in patient-derived xenograft models. Oncotarget. 2016;7(50):82200\u201312. https:\/\/doi.org\/10.18632\/oncotarget.9413.","journal-title":"Oncotarget."},{"issue":"10","key":"8242_CR50","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.15252\/emmm.201607446","volume":"9","author":"EM Tacconi","year":"2017","unstructured":"Tacconi EM, Lai X, Folio C, Porru M, Zonderland G, Badie S, et al. BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity. EMBO Mol Med. 2017;9(10):1398\u2013414. https:\/\/doi.org\/10.15252\/emmm.201607446.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"8242_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello SM, Nagari RT, Spangler RD, Rossen J, Kocak M, Bryan JG, et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nature Cancer. 2020;1(2):235\u201348. https:\/\/doi.org\/10.1038\/s43018-019-0018-6.","journal-title":"Nature Cancer"},{"issue":"5","key":"8242_CR52","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/carcin\/bgt032","volume":"34","author":"A Paranjpe","year":"2013","unstructured":"Paranjpe A, Srivenugopal KS. Degradation of NF-kappaB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells. Carcinogenesis. 2013;34(5):990\u20131000. https:\/\/doi.org\/10.1093\/carcin\/bgt032.","journal-title":"Carcinogenesis."},{"issue":"6","key":"8242_CR53","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/10715760500072172","volume":"39","author":"P Ghezzi","year":"2005","unstructured":"Ghezzi P. Regulation of protein function by glutathionylation. Free Radic Res. 2005;39(6):573\u201380. https:\/\/doi.org\/10.1080\/10715760500072172.","journal-title":"Free Radic Res"},{"issue":"7\u20138","key":"8242_CR54","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1089\/ars.2005.7.964","volume":"7","author":"P Ghezzi","year":"2005","unstructured":"Ghezzi P, Bonetto V, Fratelli M. Thiol-disulfide balance: from the concept of oxidative stress to that of redox regulation. Antioxid Redox Signal. 2005;7(7\u20138):964\u201372. https:\/\/doi.org\/10.1089\/ars.2005.7.964.","journal-title":"Antioxid Redox Signal"},{"issue":"3\u20134","key":"8242_CR55","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1089\/ars.2005.7.348","volume":"7","author":"MD Shelton","year":"2005","unstructured":"Shelton MD, Chock PB, Mieyal JJ. Glutaredoxin: role in reversible protein s-glutathionylation and regulation of redox signal transduction and protein translocation. Antioxid Redox Signal. 2005;7(3\u20134):348\u201366. https:\/\/doi.org\/10.1089\/ars.2005.7.348.","journal-title":"Antioxid Redox Signal"},{"issue":"Pt 3","key":"8242_CR56","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1042\/BJ20040591","volume":"381","author":"JV Cross","year":"2004","unstructured":"Cross JV, Templeton DJ. Oxidative stress inhibits MEKK1 by site-specific glutathionylation in the ATP-binding domain. Biochem J. 2004;381(Pt 3):675\u201383. https:\/\/doi.org\/10.1042\/BJ20040591.","journal-title":"Biochem J"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08242-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08242-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08242-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T15:25:16Z","timestamp":1672068316000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08242-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8242"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08242-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"16 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted under Investigational New Drug (IND) #100,937 and approved by the University of Utah Institutional Review Board. Informed consent was obtained from all participants. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PJS: co-founder, shareholder, and Chief Medical Officer in JSK Therapeutics. Co-founder and shareholder in Lone Star Thiotherapies. Research funding from Cantex Pharmaceuticals, Chimerix, Amgen, Aptevo, Ono, and Pfizer. Consultancy with BMS, Gilead, and Takeda. TPK: co-founder, shareholder in JSK Therapeutics, Lone Star Thiotherapies, and Cantex Pharmaceuticals. DWS: advisor and consultant to Janssen, Skyline Dx, GlaxoSmithKline, Legend Biotech, Amgen, and Celgene. NA: Consultant to Astellas, Astra Zeneca, Bayer, Bristol Myers Squibb, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Janssen, Merck, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics. Institutional research funding has been provided by Astra Zeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Glaxo Smith Kline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. The remaining authors have no relevant disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"510"}}